Nifty
Sensex
:
:
17274.30
58065.47
386.95 (2.29%)
1276.66 (2.25%)

Pharmaceuticals & Drugs - Global

Rating :
49/99

BSE: 524804 | NSE: AUROPHARMA

544.25
04-Oct-2022
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 536.00
  • 545.70
  • 533.00
  • 535.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1932237
  •  10406.33
  •  751.90
  •  494.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 31,365.29
  • 13.11
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 29,548.05
  • 1.68%
  • 1.25

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.83%
  • 0.73%
  • 8.80%
  • FII
  • DII
  • Others
  • 20.71%
  • 17.30%
  • 0.63%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.89
  • 7.34
  • 0.51

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.68
  • 3.06
  • -2.06

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 24.74
  • 2.06
  • -2.15

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.58
  • 14.23
  • 11.46

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.90
  • 2.55
  • 2.12

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.39
  • 9.55
  • 8.42

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Net Sales
6,235.92
5,701.98
9.36%
5,809.37
6,001.50
-3.20%
6,002.22
6,364.91
-5.70%
5,941.92
6,483.44
-8.35%
Expenses
5,299.44
4,492.60
17.96%
4,834.97
4,726.83
2.29%
4,985.95
4,996.33
-0.21%
4,755.20
5,050.63
-5.85%
EBITDA
936.48
1,209.38
-22.57%
974.40
1,274.67
-23.56%
1,016.27
1,368.58
-25.74%
1,186.72
1,432.81
-17.18%
EBIDTM
15.02%
21.21%
16.77%
21.24%
16.93%
21.50%
19.97%
22.10%
Other Income
40.62
109.90
-63.04%
48.88
78.10
-37.41%
64.99
133.40
-51.28%
96.58
53.75
79.68%
Interest
14.63
12.88
13.59%
9.21
18.22
-49.45%
16.13
19.49
-17.24%
10.42
15.71
-33.67%
Depreciation
279.51
279.69
-0.06%
253.57
266.00
-4.67%
299.05
276.52
8.15%
294.21
257.34
14.33%
PBT
682.96
1,026.71
-33.48%
597.74
1,069.24
-44.10%
800.87
4,019.86
-80.08%
978.67
1,213.51
-19.35%
Tax
158.61
247.74
-35.98%
17.49
259.69
-93.27%
189.49
1,057.48
-82.08%
270.91
385.73
-29.77%
PAT
524.35
778.97
-32.69%
580.25
809.55
-28.32%
611.38
2,962.38
-79.36%
707.76
827.78
-14.50%
PATM
8.41%
13.66%
9.99%
13.49%
10.19%
46.54%
11.91%
12.77%
EPS
8.88
13.14
-32.42%
9.84
13.68
-28.07%
10.32
50.32
-79.49%
11.90
13.79
-13.71%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
23,989.43
23,455.49
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
5,855.32
Net Sales Growth
-2.29%
-5.32%
7.26%
18.07%
18.83%
10.42%
8.08%
13.81%
49.64%
38.33%
 
Cost Of Goods Sold
10,660.75
9,238.91
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
5,099.89
3,275.54
2,730.00
Gross Profit
13,328.68
14,216.58
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
7,020.63
4,824.25
3,125.32
GP Margin
55.56%
60.61%
64.37%
62.25%
59.69%
63.04%
60.35%
59.32%
57.92%
59.56%
53.38%
Total Expenditure
19,875.56
19,070.95
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
4,994.37
Power & Fuel Cost
-
626.86
589.28
587.68
556.79
470.95
437.14
419.26
359.60
349.84
324.72
% Of Sales
-
2.67%
2.38%
2.54%
2.85%
2.86%
2.93%
3.04%
2.97%
4.32%
5.55%
Employee Cost
-
3,450.92
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
802.43
663.31
% Of Sales
-
14.71%
14.27%
13.94%
13.21%
12.94%
11.86%
11.18%
10.74%
9.91%
11.33%
Manufacturing Exp.
-
2,502.98
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
1,022.70
772.04
623.04
% Of Sales
-
10.67%
11.61%
10.09%
10.42%
9.79%
8.78%
9.11%
8.44%
9.53%
10.64%
General & Admin Exp.
-
1,335.03
1,473.59
1,320.69
1,006.68
1,068.22
997.32
686.38
666.38
283.49
197.83
% Of Sales
-
5.69%
5.95%
5.72%
5.15%
6.49%
6.69%
4.98%
5.50%
3.50%
3.38%
Selling & Distn. Exp.
-
1,496.67
1,564.17
1,524.75
1,125.76
1,025.85
848.43
877.14
878.98
359.60
305.98
% Of Sales
-
6.38%
6.31%
6.60%
5.75%
6.23%
5.69%
6.36%
7.25%
4.44%
5.23%
Miscellaneous Exp.
-
419.58
576.06
529.75
413.24
298.75
203.97
212.65
227.09
123.20
305.98
% Of Sales
-
1.79%
2.33%
2.29%
2.11%
1.81%
1.37%
1.54%
1.87%
1.52%
2.55%
EBITDA
4,113.87
4,384.54
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
860.95
EBITDA Margin
17.15%
18.69%
21.53%
21.06%
20.20%
22.91%
23.03%
23.11%
21.15%
26.34%
14.70%
Other Income
251.07
322.58
380.85
191.87
155.32
101.98
115.89
203.80
96.71
21.56
28.54
Interest
50.39
48.64
74.49
305.13
262.60
77.72
66.72
256.70
159.87
310.16
266.64
Depreciation
1,126.34
1,126.52
1,055.39
966.71
667.95
557.97
427.63
392.37
332.61
312.53
248.74
PBT
3,060.24
3,531.96
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
374.11
Tax
636.50
725.63
2,009.77
899.35
726.85
818.27
759.65
720.71
596.59
363.45
82.71
Tax Rate
20.80%
21.32%
27.16%
23.93%
23.53%
25.27%
24.86%
26.28%
27.52%
23.72%
22.11%
PAT
2,423.74
2,679.40
5,390.20
2,860.31
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
293.86
PAT before Minority Interest
2,424.94
2,678.36
5,389.18
2,858.86
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
291.40
Minority Interest
1.20
1.04
1.02
1.45
0.23
0.26
0.47
1.50
4.51
3.78
2.46
PAT Margin
10.10%
11.42%
21.76%
12.38%
12.07%
14.70%
15.40%
14.67%
13.00%
14.48%
5.02%
PAT Growth
-54.94%
-50.29%
88.45%
21.10%
-2.40%
5.37%
13.49%
28.42%
34.35%
299.12%
 
EPS
41.37
45.73
92.00
48.82
40.31
41.30
39.20
34.54
26.89
20.02
5.02

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
24,575.98
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
2,605.76
Share Capital
58.59
58.59
58.59
58.59
58.59
58.59
58.52
29.20
29.15
29.12
Total Reserves
24,517.39
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
2,576.64
Non-Current Liabilities
903.10
807.27
555.09
358.13
594.11
102.07
583.85
1,591.60
1,493.91
1,225.26
Secured Loans
249.21
168.49
0.00
48.88
451.20
177.59
380.10
773.54
1,101.31
1,084.11
Unsecured Loans
0.00
0.00
0.00
131.07
0.00
3.81
362.71
587.93
178.05
64.15
Long Term Provisions
171.79
157.11
74.71
46.54
55.86
39.13
23.36
24.35
9.18
9.00
Current Liabilities
8,155.98
10,665.05
11,384.64
12,020.57
8,665.89
6,605.60
7,840.22
6,136.40
4,220.04
3,430.83
Trade Payables
2,703.05
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
2,457.03
2,051.13
1,351.20
963.75
Other Current Liabilities
3,106.51
2,684.31
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
1,364.95
387.68
150.87
Short Term Borrowings
2,117.83
4,803.78
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
2,236.12
Short Term Provisions
228.59
382.28
511.72
384.67
294.23
261.36
132.93
218.24
126.60
80.09
Total Liabilities
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
Net Block
10,532.09
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
2,638.87
Gross Block
15,943.09
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
3,763.47
Accumulated Depreciation
5,411.00
4,239.75
3,044.79
2,022.77
1,374.10
801.71
390.14
1,740.49
1,461.29
1,124.60
Non Current Assets
15,510.44
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
5,419.57
4,610.93
3,858.59
3,136.10
Capital Work in Progress
3,747.20
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
848.14
370.35
256.67
167.82
Non Current Investment
618.30
431.22
554.69
360.20
311.52
245.85
122.94
0.14
19.76
22.24
Long Term Loans & Adv.
575.33
658.44
378.34
396.64
261.91
256.48
236.56
455.27
789.04
237.82
Other Non Current Assets
37.52
53.03
36.61
38.62
86.93
81.29
32.24
30.25
18.40
18.66
Current Assets
18,122.69
19,823.51
16,412.51
15,332.30
12,178.16
9,206.18
10,294.35
8,298.80
5,631.18
4,136.75
Current Investments
378.85
159.79
0.02
0.02
0.02
0.02
0.02
19.65
0.03
0.04
Inventories
7,553.85
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
1,923.59
Sundry Debtors
4,012.26
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
4,606.68
3,539.17
2,636.57
1,596.98
Cash & Bank
4,190.01
5,474.28
2,842.15
1,957.18
1,262.25
513.48
800.26
469.11
178.58
208.45
Other Current Assets
1,987.72
601.29
489.35
1,919.82
1,977.28
1,596.81
831.25
659.57
448.46
407.69
Short Term Loans & Adv.
1,514.67
1,058.30
1,065.96
795.90
753.96
512.09
366.88
387.90
237.22
207.51
Net Current Assets
9,966.71
9,158.46
5,027.87
3,311.73
3,512.27
2,600.58
2,454.13
2,162.40
1,411.14
705.92
Total Assets
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
5,016.48
3,329.05
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
1,236.81
646.28
274.87
PBT
3,372.74
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
374.11
Adjustment
1,344.13
-1,662.64
1,091.17
813.95
535.02
408.92
487.50
406.28
515.12
441.54
Changes in Working Capital
1,557.80
-1,066.65
307.91
-1,484.50
-1,123.12
582.52
-1,079.41
-841.73
-1,057.41
-421.56
Cash after chg. in Working capital
6,274.67
4,614.30
5,142.12
2,420.80
2,653.08
4,052.28
2,152.39
1,732.40
990.23
394.09
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,258.19
-1,285.25
-760.84
-769.83
-698.56
-773.70
-732.63
-495.59
-343.95
-119.22
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,211.56
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
-1,397.97
-818.74
-246.34
Net Fixed Assets
1,473.74
-428.03
-760.60
-799.00
-771.00
-1,092.24
125.11
-533.87
-141.02
-224.46
Net Investments
-1,574.43
-2,482.52
-188.35
-371.56
-285.55
-498.60
-170.60
-140.13
-164.64
-78.98
Others
-3,110.87
3,509.24
-618.69
-1,732.03
-870.04
-196.20
-1,399.72
-723.97
-513.08
57.10
Cash from Financing Activity
-2,969.27
-1,364.94
-1,947.18
1,919.06
864.15
-1,915.26
365.44
93.21
117.64
108.09
Net Cash Inflow / Outflow
-1,164.35
2,562.80
866.46
667.44
892.08
-423.72
339.99
-67.95
-54.82
136.62
Opening Cash & Equivalents
5,329.91
2,746.82
1,875.58
1,209.94
318.03
743.49
403.81
148.02
202.73
65.64
Closing Cash & Equivalent
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
319.63
743.50
461.10
148.02
202.73

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
419.46
374.29
287.16
237.08
199.36
159.96
124.50
88.29
64.33
44.74
ROA
7.99%
17.34%
10.39%
10.00%
13.07%
14.44%
14.13%
14.03%
13.95%
4.32%
ROE
11.52%
27.81%
18.62%
18.47%
22.99%
27.57%
32.51%
35.29%
36.79%
11.78%
ROCE
12.82%
30.33%
18.79%
17.97%
22.72%
24.92%
27.35%
27.18%
27.18%
11.17%
Fixed Asset Turnover
3.24
3.73
4.12
4.36
2.44
2.96
2.79
2.55
2.08
1.75
Receivable days
28.69
29.37
29.85
29.56
64.66
89.16
106.53
91.84
93.55
86.28
Inventory Days
63.29
62.82
57.72
59.64
112.70
101.43
100.27
88.91
94.82
105.51
Payable days
108.60
111.03
53.30
58.56
67.77
75.73
81.70
67.49
71.06
57.79
Cash Conversion Cycle
-16.62
-18.84
34.27
30.63
109.58
114.86
125.10
113.25
117.31
134.00
Total Debt/Equity
0.10
0.23
0.33
0.50
0.41
0.36
0.69
0.86
1.01
1.32
Interest Cover
70.98
100.33
13.32
12.76
42.66
46.80
11.69
14.56
5.94
2.40

News Update:


  • Aurobindo Pharma’s arm receives EIR for Raleigh plant
    22nd Sep 2022, 11:42 AM

    With this, the USFDA pre-approval inspection and GMP inspection are concluded

    Read More
  • Aurobindo Pharma’s arm gets nod to expand mammalian cell culture manufacturing facility
    2nd Sep 2022, 11:20 AM

    The capital expenditure for ramping up capacities is estimated to be around Rs 300 crore

    Read More
  • USFDA completes inspection at Aurobindo Pharma’s Raleigh unit with 1 observation
    29th Aug 2022, 12:48 PM

    The observation is procedural in nature and there are no data integrity issues

    Read More
  • Aurobindo Pharma’s arm gets nod to manufacture, market Medroxyprogesterone Acetate Injectable Suspension
    24th Aug 2022, 10:38 AM

    The approved product has an estimated market size of around $ 62 million for the twelve months ending June 2022

    Read More
  • Aurobindo Pharma acquires 51% stake in GLS Pharma
    18th Aug 2022, 11:15 AM

    Post-acquisition GLS Pharma has become the subsidiary of the company

    Read More
  • Aurobindo Pharma’s arm receives USFDA’s approval for Vasopressin Injection
    16th Aug 2022, 09:53 AM

    The product is being launched immediately

    Read More
  • Aurobindo Pharma reports 32% fall in Q1 consolidated net profit
    12th Aug 2022, 12:07 PM

    Total consolidated income of the company increased by 8% at Rs 6,276.54 crore for Q1FY23

    Read More
  • Aurobindo Pharma - Quarterly Results
    11th Aug 2022, 17:58 PM

    Read More
  • USFDA completes inspection at Unit VII of Aurobindo Pharma
    5th Aug 2022, 14:48 PM

    The Company’s Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, received an Establishment Inspection Report

    Read More
  • Aurobindo Pharma gets 3 observations from USFDA for Andhra Pradesh unit
    3rd Aug 2022, 10:50 AM

    The company will respond to the USFDA within the stipulated timeline and work closely with the regulator to address the observations at the earliest

    Read More
  • Aurobindo Pharma’s arm gets USFDA nod for Triamcinolone Acetonide injectable suspension
    6th Jul 2022, 14:39 PM

    The product is being launched this month

    Read More
  • Aurobindo Pharma acquires business and certain assets of Veritaz Healthcare
    5th Jul 2022, 09:59 AM

    Earlier, the company had received approval of the Board of Directors of the Company for the acquisition of the same

    Read More
  • Aurobindo Pharma gets warning letter from SEBI
    27th Jun 2022, 16:58 PM

    The SEBI warning letter observes that the Company had disclosed very limited and restricted information

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.